However, a combination immunotherapy consisting of anti-programmed cell death ligand-1 (anti-PD-L1) (atezolizumab/Tecentriq) and anti-vascular endothelial growth factor (anti-VEGF) (bevacizumab/Avastin) antibodies demonstrated better overall and progression-free survival outcomes over sorafenib in treatment-naïve advanced HCC patients in the IMbrave150 trial, and is currently being recommended as the first line of treatment for advanced HCC [21]. Here, VEGFA is linked to hepatocellular carcinoma.